http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20170064410-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3fe76949cd566430d9d83a068bab21e1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_092500dd35f65485445a5f6b9169a3cc |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-02 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-93 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y601-01002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-25 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-25 |
| filingDate | 2015-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_887eaad8babedad97e0aff0d1f64bcef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c5135c6a525b4b98e1ec5b2a63560b8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5fda41131a4d643eeb74d81ca995779 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f42fda3b472654549ac253d760d64556 |
| publicationDate | 2017-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20170064410-A |
| titleOfInvention | Methods for screening anti-inflammatory agents or immune-stimulating agents or anti-cancer agents using interactions between WRS and MD2 |
| abstract | The present invention relates to a therapeutic agent for inflammatory diseases, an immunological enhancer or an anticancer agent screening method using the binding of tryptophan thiolatedene synthase (WRS) to MD2, and more particularly to a method for screening a WRS or a fragment thereof and MD2 A screening method comprising contacting an MD2-TLR4 complex and measuring a binding level to increase the binding force of the W2S or its fragment and the MD2 or MD2-TLR4 complex to an immune enhancer or an anticancer agent; As a prophylactic or therapeutic agent for an inflammatory disease. Using the binding mechanism of WRS and TLR4-MD2 complexes as disclosed by the present inventors, a test agent that increases the binding force of WRS or its fragment and the MD2 or MD2-TLR4 complex is selected as a drug candidate substance, and an immune enhancer or anti- Can be usefully used for development. In addition, the test agent selected by decreasing the binding force can be usefully used for the development of a prophylactic or therapeutic agent for inflammatory diseases. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019226515-A1 |
| priorityDate | 2015-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 800.